[go: up one dir, main page]

EP2566465A2 - Formulations stables de rosuvastatine - Google Patents

Formulations stables de rosuvastatine

Info

Publication number
EP2566465A2
EP2566465A2 EP11725996A EP11725996A EP2566465A2 EP 2566465 A2 EP2566465 A2 EP 2566465A2 EP 11725996 A EP11725996 A EP 11725996A EP 11725996 A EP11725996 A EP 11725996A EP 2566465 A2 EP2566465 A2 EP 2566465A2
Authority
EP
European Patent Office
Prior art keywords
formulation
rosuvastatin
range
stabilizer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11725996A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/09397A external-priority patent/TR201009397A2/xx
Application filed by Individual filed Critical Individual
Publication of EP2566465A2 publication Critical patent/EP2566465A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Definitions

  • the present invention relates to new rosuvastatin formulations prepared so as to be used in the treatment of hyperlipidemia.
  • the characteristic features of the formulations are that said formulations comprise rosuvastatin on effective amounts; a pharmaceutically acceptable phosphate salt is used as the stabilizer, and the ratio of rosuvastatin to the stabilizer in the formulation is in the range of 0.5-20 by weight.
  • Rosuvastatin which has the chemical name (3i?,5S,6E)-7-[4-(4-fluorophenyl)-6-(l-methylethyl)-2[methyl(methylsulphonyl)amino]-5- pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid is a HMG Co A enzyme inhibitor and it is displayed in formula (I):
  • rosuvastatin which is displayed in formula (I) in the patent numbered US5260440, inhibits the activation of the enzyme named HMG-CoA reductase that is responsible for cholesterol synthesis in the body and prevents cholesterol formation and it is effective in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.
  • Statin derivative cholesterol absorption inhibitors can also be used in combination with cardiovascular active agents; for instance fibric acid derivatives, calcium channel blockers and cholesterol absorption inhibitors.
  • rosuvastatin easily disintegrates as affected by factors such as moisture and light, and this constitutes a serious impediment to development of stable rosuvastatin formulations and combinations.
  • Rosuvastatin calcium is transformed into lactone as a result of "intramolecular esterification" which occurs between carboxylic acid in its structure and hydroxyl groups on ⁇ and ⁇ carbons of this carboxylic acid.
  • the reaction takes place in acidic environment and the basic agents cause the reaction to revert back.
  • the main disintegration products (3R, 5S) that arise as a result of the disintegration of rosuvastatin are lacton and oxidation products.
  • Richter Gedeon NYRT disclosed formulations comprising rosuvastatin calcium as the active agent and calcium acetate, magnesium hydroxide, calcium gluconate, calcium glycerophosphate or aluminum hydroxide as the stabilizing agent in the patent application WO2008035128(Al).
  • the first aspect of the invention relates to an enhanced pharmaceutical formulation comprising rosuvastatin in a therapeutically effective amount and a pharmaceutically acceptable phosphate salt as the stabilizer.
  • the invention discloses stable rosuvastatin formulations which have longer shelf life than known formulations and in which the ratio of rosuvastatin to the stabilizer is in the range of 0.5- 20 by weight.
  • the characteristic feature of the formulations is that said formulations comprise rosuvastatin in an effective amount, a pharmaceutically acceptable phosphate salt and or pharmaceutical derivatives thereof, and the ratio of rosuvastatin to the stabilizer is in the range of 0.5-20 by weight.
  • Another characteristic feature of the formulations of the present invention is that the ratio of rosuvastatin to the stabilizer used in said formulations is preferably in the range of 0.5-15, more preferably in the range of 0.5-8 by weight.
  • phosphate salt used throughout the text comprises phosphate salts and all pharmaceutically acceptable derivatives thereof. 'Derivatives' refers to all pharmaceutically acceptable hydrates and antihydrates of said phosphate salt.
  • Said phosphate salts can be selected from a group comprising monobasic, dibasic or tribasic calcium, magnesium, aluminum, iron phosphate salts and/or hydrates thereof.
  • the preferred phosphate salt is in dihydrate form though it is more preferably dibasic calcium phosphate dihydrate and/or pharmaceutically acceptable derivatives thereof.
  • Rosuvastatin used in the formulations of the present invention is in the form of pharmaceutically acceptable salt thereof, preferably in calcium salt form.
  • Rosuvastatin calcium is used in a particular particle size range in formulations of the present invention.
  • D(50) particle size for rosuvastatin calcium is in the range of 5 to 80 micron, preferably in the range of 20 to 80 micron, more preferably in the range of 30 to 80 micron;
  • D(90) particle size is in the range of 100 to 400 micron, preferably in the range of 100 to 350 micron, more preferably in the range of 100 to 300 micron.
  • D(50) particle size used in the text refers to the particle size of 50% of rosuvastatin particles by volume and "D(90) particle size” refers to the particle size of 90% of rosuvastatin particles by volume, which were measured in the device Malvern Mastersizer 2000 S (Scirocco 2000) by dry method.
  • the formulations according to the present invention can comprise at least one sterol absorption inhibitor in an effective amount as a second active agent.
  • the sterol absorption inhibitor used in rosuvastatin formulations of the present invention is selected preferably from ezetimibe and/or its pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline and amorphous forms and/or combinations thereof.
  • the formulations of the present invention comprise;
  • ⁇ at least one pharmaceutically acceptable disintegrant in the range of 5% to 20% by weight, • one or more pharmaceutically acceptable excipients in the range of 1% to 20% by weight.
  • the formulations can optionally comprise coating materials.
  • substances such as antioxidants, chelating agents, alkalinizing agents and photoprotectives can be used as the stabilizer.
  • the stabilizer/stabilizers used in the formulations of the present invention are preferably alkalinizing agents and they can be selected from, but not limited to, a group comprising alkaline metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulfate, magnesium acetate, magnesium silicate, magnesium aluminate; and organic compounds such as primary, secondary and tertiary amines, cyclic amines,
  • the formulations of the present invention can comprise other pharmaceutically acceptable components such as additives and excipients selected from a group comprising binders, disintegrants, viscosity enhancing agents, filling materials, desiccants, lubricants, diluents, binders, glidants, wetting agents, anti-adhesive agents, solvents, sweeteners.
  • additives and excipients selected from a group comprising binders, disintegrants, viscosity enhancing agents, filling materials, desiccants, lubricants, diluents, binders, glidants, wetting agents, anti-adhesive agents, solvents, sweeteners.
  • the filling materials used in the present invention comprise one or more components selected from the group comprising lactose, sugar, starch, modified starch, mannitol, sorbitol, inorganic salts, microcrystalline cellulose, cellulose, calcium sulfate, xylitol and lactitol.
  • the disintegrant of the present invention enables the dosage form to disperse easily and rapidly in water and it is significant from this aspect.
  • the disintegrants can be selected from polymers having high disintegrating characteristics such as cross-linked hydroxypropyl cellulose, polyvinylpyrrolidone, high molecular weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, crospovidone or colloidal silicone dioxide, alginic acid, sodium alginate, corn starch.
  • the disintegrant preferred is crospovidone and its amount in the formulation is in the range of 5% to 20%.
  • the anti-adhesive substances of the present invention are used in order to prevent the mixture comprising active agent to adhere on device and machine surfaces during the process and create a rough surface.
  • the substances used for this purpose comprise one or more components selected from the group comprising talc, colloidal silicon dioxide (Aerosil, Syloid, Cab-O-Sil), magnesium stearate and corn starch.
  • the binders of the present invention comprise one or more components selected from the group comprising potato starch, wheat starch or corn starch; microcrystalline cellulose, for instance Avicel®, Filtrak®, Heweten® or Pharmacel® products; hydroxypropyl cellulose, hydroxyethyl cellulose; hydroxypropylmethyl cellulose, for instance hydroxypropylmethyl cellulose- Tip 2910 USP; hypromellose and polyvinylpyrrolidone, for instance Povidone® K30(BASF); lactose, guar gum, pectin, gelatin, sodium alginate.
  • microcrystalline cellulose for instance Avicel®, Filtrak®, Heweten® or Pharmacel® products
  • hydroxypropyl cellulose hydroxyethyl cellulose
  • hydroxypropylmethyl cellulose for instance hydroxypropylmethyl cellulose- Tip 2910 USP
  • hypromellose and polyvinylpyrrolidone for instance Povidone® K30(BASF)
  • the lubricants of the present invention comprise one or more components selected from the group comprising metallic stearates (e.g. magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (e.g. sodium stearil fumarate), fatty acids (e.g. stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffines, hydrogenated vegetable oil, leucine, polyethylene glycols (PEG), metallic lauryl sulfates (e.g. sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate, sodium acetate and talc and/or hydrates thereof.
  • metallic stearates e.g. magnesium stearate, calcium stearate, aluminum stearate
  • fatty acid esters e.g. sodium stearil fumarate
  • fatty acids e.g. stearic acid
  • fatty alcohols g
  • the lubricant used in the formulations of the present invention is preferably magnesium stearate.
  • the diluents of the present invention comprise one or more components selected from the group comprising alkaline metal carbonates, cellulose derivatives (e.g. microcrystalline cellulose, cellulose acetate etc.), dextrin, fructose, dextrose, glyceryl palmitostearate, lactitol, lactose, direct compression-lactose, maltose, mannitol, simethicone, sorbitol, starch, talc, xylitol and/or hydrates and/or derivatives thereof.
  • the diluent used in the formulations of the present invention is preferably direct compression-lactose.
  • the solvents of the present invention comprise one or more components selected from the group comprising toluene, benzene, acetone, methyl acetate, tetrahydrofurane, heptanes, hexane, acetonitrile, alcohol and/or alcohol mixtures.
  • the film coating material of the present invention is composed of lactose, hydroxypropyl methyl cellulose, triacetine, titanium dioxide, polyvinyl alcohol, talc, lecithin, polyethylene glycol and/or mixtures thereof. Quality of the coating material plays an important role in maintaining the stability of formulations comprising rosuvastatin during shelf life.
  • the coating material according to the present invention comprises sufficient amounts of talc, lecithine and optionally at least one of the components listed above or mixtures of these components in addition.
  • the coating material used to coat the tablet dosage form of the present invention is approximately in the range of 0.5% to 10% of the total tablet weight, preferably in the range of 1% to 5%.
  • the pharmaceutical formulations to be administered orally can be in tablet, capsule, soluble tablet, effervescent tablet, chewable tablet, coated tablet, soluble granule, soluble powder, emulsion, suspension, solution form.
  • the oral dosage form according to the present invention is preferably film coated tablet and the formulations of the present invention can be produced by any production method known in the prior art.
  • Rosuvastatin calcium at a particular particle size, at least one pharmaceutically acceptable disintegrant, the diluent and the stabilizer are mixed,
  • the obtained mixture is sieved preferably through a 25 mesh sieve and treated with the lubricant,
  • the final mixture is sent to the compression machine and tablets are compressed by imposing a compression force in the range of 10 kN to 200 kN, preferably in the range of 30 kN to 200 kN, more preferably in the range of 30 kN to 150 kN,
  • the compressed tablets are film coated by the coating material obtained dissolving the sufficient amount of coating material in deionized water.
  • rosuvastatin calcium, dibasic calcium phosphate dihydrate, the disintegrant and the diluent are mixed and sieved.
  • Magnesium stearate is added into the mixture obtained and the blend is mixed again.
  • the final mixture is loaded to tablet compression machine and tablets are compressed imposing 80 kN compression force.
  • the compressed tablets are coated with the film coating solution prepared by dissolving the coating material in a sufficient amount of deionized water in advance and the tablet formulations are finalized.
  • combination tablet For the combination tablet to be prepared according to the formulation given below, two active agents are formulated separately, and then the two mixtures obtained are mixed. The final mixture is loaded to tablet compression machine and tablets are compressed. The tablets prepared are film coated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne de nouvelles formulations de rosuvastatine préparées de manière à être utilisées dans le traitement de l'hyperlipidémie. Ces formulations se caractérisent en ce qu'un sel de phosphate pharmaceutiquement acceptable est utilisé comme stabilisant et en ce que le rapport entre la rosuvastatine et le stabilisant dans la formulation est compris entre 0,5 et 20 en poids.
EP11725996A 2010-05-04 2011-05-03 Formulations stables de rosuvastatine Withdrawn EP2566465A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR201003542 2010-05-04
TR2010/09397A TR201009397A2 (tr) 2010-11-11 2010-11-11 Rosuvastatin içeren farmasötik bileşimler.
PCT/TR2011/000135 WO2011139256A2 (fr) 2010-05-04 2011-05-03 Formulations stables de rosuvastatine

Publications (1)

Publication Number Publication Date
EP2566465A2 true EP2566465A2 (fr) 2013-03-13

Family

ID=44462116

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11725996A Withdrawn EP2566465A2 (fr) 2010-05-04 2011-05-03 Formulations stables de rosuvastatine

Country Status (2)

Country Link
EP (1) EP2566465A2 (fr)
WO (1) WO2011139256A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3243506A1 (fr) 2016-05-09 2017-11-15 Adamed sp. z o.o. Composition pharmaceutique

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201009397A2 (tr) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
US10376470B2 (en) 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
PT2844233T (pt) * 2012-05-01 2020-06-25 Althera Life Sciences Llc Formulação de comprimido oral que consiste numa combinação fixa de rosuvastatina e ezetimiba para o tratamento de hiperlipidemia e doenças cardiovasculares
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR102055894B1 (ko) * 2016-11-15 2019-12-13 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제
GR1009727B (el) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
CN117137876B (zh) * 2023-08-07 2024-12-03 福建东瑞制药有限公司 瑞舒伐他汀钙片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU2003245736A1 (en) * 2002-02-14 2003-09-04 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
HU227610B1 (en) 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008101723A2 (fr) * 2007-02-23 2008-08-28 Krka Composition pharmaceutique comprenant un inhibiteur d'absorption du cholestérol
WO2009024889A2 (fr) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
WO2011019326A2 (fr) * 2009-07-02 2011-02-17 Mahmut Bilgic Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011139256A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3243506A1 (fr) 2016-05-09 2017-11-15 Adamed sp. z o.o. Composition pharmaceutique
WO2017194432A1 (fr) 2016-05-09 2017-11-16 Adamed Sp. Z O.O. Composition pharmaceutique

Also Published As

Publication number Publication date
WO2011139256A3 (fr) 2012-05-18
WO2011139256A2 (fr) 2011-11-10

Similar Documents

Publication Publication Date Title
EP2566465A2 (fr) Formulations stables de rosuvastatine
EP2448919A2 (fr) Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
WO2013066279A1 (fr) Formes pharmaceutiques solides contenant de l'ézétimibe
WO2009024889A2 (fr) Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
CA2798363A1 (fr) Formulation pharmaceutique sous la forme de comprimes bicouches comprenant un inhibiteur de hmg-coa reductase et d'irbesartan
WO2008068217A2 (fr) Composition pharmaceutique
EP2448564A2 (fr) Formulation pharmaceutique améliorant la solubilité
CA2692862C (fr) Compositions stables
JP7094944B2 (ja) ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法
EP2328563B1 (fr) Preparation pharmaceutique ameliorant la solubilite
EP2588103A1 (fr) Combinaison d'atorvastatine et d'aspirine destinée à être utilisée dans le traitement de maladies cardiovasculaires
CA2730665C (fr) Forme galenique contenant une statine
EA028969B1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
WO2006006021A2 (fr) Compositions pharmaceutiques stabilisees
WO2012002921A1 (fr) Formes galéniques multiples comprenant du fénofibrate ou de l'acide fénofibrique combiné à des inhibiteurs de hmg co a réductase tels que les statines
KR20110097168A (ko) 고지혈증 치료용 약제학적 복합제제
CN114173786A (zh) 包含hmg-辅酶a还原酶抑制剂和非诺贝特的药物组合物
US20090233898A1 (en) Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe
WO2010140992A1 (fr) Compositions pharmaceutiques stables contenant du calcium rosuvastatine
KR101302306B1 (ko) 고지혈증 복합제
KR101098597B1 (ko) 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물
RU2850454C9 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОРЫ HMG-CoA РЕДУКТАЗЫ И ФЕНОФИБРАТ
RU2508109C2 (ru) Фармацевтическая композиция для лечения нарушений липидного обмена
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
WO2009091346A2 (fr) Formulation pharmaceutique stable et procédés de préparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121130

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141217